MEETING AGENDA

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333.

I. CALL TO ORDER
1:00 PM
A. Roll Call & Introductions
B. Conflict of Interest Declaration
C. Approval of Agenda and Minutes
D. Department Update
E. Legislative Update

1:20 PM
II. CONSENT AGENDA TOPICS
A. Quarterly Utilization Reports
B. Oncology Prior Authorization Updates
C. DUR OLD BUSINESS: CGRP Inhibitors
   1. Public Comment

1:25 PM
III. DUR ACTIVITIES
A. ProDUR Report
B. RetroDUR Report
C. Oregon State Drug Review
   1. Psychotropic Use in Youth Enrolled in the Oregon Health Plan and Youth in Foster Care with an Emphasis on Antipsychotic Prescription
   2. COVID-19 Therapeutics Update: Where Are We Now?

IV. DUR NEW BUSINESS
1:40 PM
A. Sublingual Buprenorphine Quantity Limit Policy Evaluation
   1. Policy Evaluation/Prior Authorization Criteria
   2. Public Comment
   3. Discussion and Clinical Recommendations to OHA
V. PREFERRED DRUG LIST NEW BUSINESS

2:00 PM A. Daybue™ (trofinetide) New Drug Evaluation
1. New Drug Evaluation/Prior Authorization Criteria
2. Public Comment
3. Discussion and Clinical Recommendations to OHA

D. Moretz (OSU)

2:15 PM B. BPH Class Update
1. Class Update/Prior Authorization Criteria
2. Public Comment
3. Discussion and Clinical Recommendations to OHA

K. Sentena (OSU)

2:35 PM C. Vowst™ (oral fecal microbiota spores, live-brpk) New Drug Evaluation
1. New Drug Evaluation/Prior Authorization Criteria
2. Public Comment
3. Discussion and Clinical Recommendations to OHA

D. Moretz (OSU)

2:50 PM BREAK

3:05 PM D. Non-injectable Allergen Immunotherapy Class Review
1. Class Review/Prior Authorization Criteria
2. Public Comment
3. Discussion and Clinical Recommendations to OHA

D. Moretz (OSU)

3:20 PM E. Gene Therapies for Beta-thalassemia and Hemophilia B
DERP Summary
1. DERP Summary/Prior Authorization Criteria
2. Public Comment
3. Discussion and Clinical Recommendations to OHA

S. Fletcher (OSU)

3:40 PM F. Endocrine Therapies Class & Prior Authorization Updates
1. GnRH Agonists Class Update/Prior Authorization Criteria
2. Estrogens Prior Authorization Criteria
3. Testosterone Prior Authorization Criteria
4. Public Comment
5. Discussion and Clinical Recommendations to OHA

D. Moretz (OSU)
S. Servid (OSU)

4:10 PM VI. EXECUTIVE SESSION

4:50 PM VII. RECONVENE for PUBLIC RECOMMENDATIONS

VIII. ADJOURN